Table 1 Characteristics of the boosted cohort by vaccination seriesa

From: Comparative mRNA booster effectiveness against death or hospitalization with COVID-19 pneumonia across at-risk US Veteran populations

 

Overall

mRNA-1273 ×3

BNT162b2 ×3

N

1,703,189

917,954

785,235

Male, n (%)

1,566,828 (92.0)

852,107 (92.8)

714,721 (91.0)

Female, n (%)

136,361 (8.0)

65,847 (7.2)

70,514 (9.0)

Age, median (q1.0, q3)

72 (63.0, 76.0)

72 (64.0, 77.0)

71 (61.0, 76.0)

   18.0–34, n (%)

25,570 (1.5)

10,609 (1.2)

14,961 (1.9)

   35.0–49, n (%)

115,597 (6.8)

51,286 (5.6)

64,311 (8.2)

   50.0–64, n (%)

356,321 (20.9)

179,032 (19.5)

177,289 (22.6)

   65.0–74, n (%)

625,953 (36.8)

341,048 (37.2)

284,905 (36.3)

   >75.0, n (%)

579,748 (34.0)

335,979 (36.6)

243,769 (31.0)

Raceb, n (%)

  American Indian or Alaska Native

11,220 (0.7)

5995 (0.7)

5225 (0.7)

  Asian

24,503 (1.4)

11,757 (1.3)

12,746 (1.6)

  Black or African American

330,079 (19.4)

148,949 (16.2)

181,130 (23.1)

  Missing

108,998 (6.4)

57,135 (6.2)

51,863 (6.6)

  More than one race

13,469 (0.8)

6939 (0.8)

6,530 (0.8)

  Native Hawaiian or other Pacific Islander

15,155 (0.9)

7812 (0.9)

7343 (0.9)

  White

1,199,765 (70.4)

679,367 (74.0)

520,398 (66.3)

Hispanic or Latino Ethnicity (regardless of race), n (%)

120,447 (7.1)

66,661 (7.3)

53,786 (6.8)

Married, n (%)

1,018,655 (59.8)

560,871 (61.1)

457,784 (58.3)

Urbanc, n (%)

1,170,612 (68.7)

571,598 (62.3)

599,014 (76.3)

BMI, median (q1.0, q3)

29 (26.0, 33.3)

29 (26.0, 33.3)

29 (26.1, 33.4)

BMI_cat

   <18.5, n (%)

11,710 (0.7)

6275 (0.7)

5435 (0.7)

   18.5–24.9, n (%)

280,883 (16.5)

151,927 (16.6)

128,956 (16.4)

   25.0–29.9, n (%)

589,295 (34.6)

316,639 (34.5)

272,656 (34.7)

   ≥30.0, n (%)

721,252 (42.3)

385,192 (42.0)

336,060 (42.8)

   Unknown, n (%)

100,049 (5.9)

57,921 (6.3)

42,128 (5.4)

Hypertension

1,043,181 (61.2)

578,501 (63.0)

464,680 (59.2)

Diabetes

554,540 (32.6)

308,289 (33.6)

246,251 (31.4)

CKDd

355,021 (20.8)

199,994 (21.8)

155,027 (19.7)

IHD

291,422 (17.1)

166,077 (18.1)

125,345 (16.0)

COPD bronchiectasis

196,384 (11.5)

114,691 (12.5)

81,693 (10.4)

CHF

96,188 (5.6)

53,640 (5.8)

42,548 (5.4)

Immunocompromisede

120,111 (7.1)

64,316 (7.0)

55,795 (7.1)

Cancer–solid organ

59,172 (3.5)

31,527 (3.4)

27,645 (3.5)

Severe CKDf

43,843 (2.6)

26,242 (2.9)

17,601 (2.2)

Stroke TIA

45,239 (2.7)

24,295 (2.6)

20,944 (2.7)

Dementia

32,089 (1.9)

18,086 (2.0)

14,003 (1.8)

Cirrhosis

26,480 (1.6)

13,133 (1.4)

13,347 (1.7)

Cancerg–lymphoma leukemia

21,103 (1.2)

11,804 (1.3)

9299 (1.2)

Dialysis

12,780 (0.8)

6924 (0.8)

5856 (0.7)

Cancerg–other

10,752 (0.6)

5425 (0.6)

5327 (0.7)

Date of first dose of vaccination series, by 3.0-month period

   12/2020−02/2021

1,117,531 (65.6)

624,545 (68.0)

492,986 (62.8)

   03/2021−05/2021

560,429 (32.9)

282,717 (30.8)

277,712 (35.4)

   06/2021−08/2021

22,708 (1.3)

9782 (1.1)

12,926 (1.6)

   09/2021−11/2021

2513 (0.1)

907 (0.1)

1606 (0.2)

   12/2021−02/2022

8 (0.0)

3 (0.0)

5 (0.0)

Current smoker, n (%)

352,343 (20.7)

190,127 (20.7)

162,216 (20.7)

Alcohol use disorderh, n (%)

118,757 (7.0)

61,581 (6.7)

57,176 (7.3)

Substance use disorderi, n (%)

74,262 (4.4)

37,537 (4.1)

36,725 (4.7)

Housing problemsj, n (%)

60,951 (3.6)

30,528 (3.3)

30,423 (3.9)

Median follow-up time (IQR), days

188 (163.0, 213.0)

180 (159.0, 202.0)

199 (168.0, 224.0)

Median time elapsed between initial dose and booster (IQR), days

270 (246.0, 295.0)

280 (258.0, 301.0)

258 (237.0, 282.0)

High-risk populations, n (%)

1,592,704 (93.5)

867,665 (94.5)

725,039 (92.3)

Age >65.0 and no high-risk co-morbid conditions, n (%)

215,177 (12.6)

118,313 (12.9)

96,864 (12.3)

High-risk co-morbid conditions (not immunocompromised), n (%)

1,188,470 (69.8)

647,603 (70.5)

540,867 (68.9)

Immunocompromisede, n (%)

189,057 (11.1)

101,749 (11.1)

87,308 (11.1)

Age <65.0 and no co-morbid conditions, n (%)

110,485 (6.5)

50,289 (5.5)

60,196 (7.7)

  1. aFull Table 1 data found in Supplement Supplementary Table 2.
  2. bRace/ethnicity was assessed using self-identified data found in Veteran Health Records.
  3. cUrban/rural was assessed using defined based on the Rural Urban Commuting Area (RUCA) categories developed by the Department of Agriculture and Health and Human Services’ Health Resource and Services Administration.
  4. dCKD defined as having a glomerular filtration rate between 30 and 60.
  5. eImmunocompromised definition based on medications and history of cancer (see supplement for list of meds).
  6. fSevere CKD defined as having a glomerular filtration rate <30.
  7. gCancer definition based on diagnosis codes. 2 outpatient or 1 inpatient diagnosis code in the VHA (see supplement).
  8. hAlcohol use disorder defined as 1 outpatient or 1 inpatient code within 2 years of index.
  9. iIncluding cannabis, opioids, inhalants.
  10. jHousing problems defined as homelessness, inadequate housing, other problems related to housing and economic circumstances.
  11. BMI body mass index, CHF chronic heart failure, CKD chronic kidney disease, COPD chronic obstructive pulmonary disease, TIA transient ischemic attack.
Back to article page